| Hernan Alberto Sanchez Trejo, MD | |
|
255 Baptist Blvd Ste 407, Columbus, MS 39705-2004 | |
| (662) 241-4223 | |
| (662) 241-4460 |
| Full Name | Hernan Alberto Sanchez Trejo |
|---|---|
| Gender | Male |
| Speciality | General Surgery |
| Experience | 14 Years |
| Location | 255 Baptist Blvd Ste 407, Columbus, Mississippi |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1669887105 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | 27492 (Mississippi) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mississippi Homecare Of Eupora | Eupora, MS | Home health agency |
| Baptist Memorial Hospital Golden Triangle Inc | Columbus, MS | Hospital |
| Baptist Memorial Hospital North Ms | Oxford, MS | Hospital |
| Baptist Memorial Hospital Union County | New albany, MS | Hospital |
| North Mississippi Medical Center | Tupelo, MS | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Baptist Memorial Medical Group, Inc. | 5193610228 | 433 |
News Archive
Oncolytics Biotech Inc. today announced that it has received a letter of approval from the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to conduct its Phase 3 trial examining REOLYSIN in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers. This is the same trial that the Company previously reached an agreement on with the U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) process.
Findings published in the Journal of Pediatrics describe growth factors in cord blood that may identify premature infants at risk for bronchopulmonary dysplasia-associated pulmonary hypertension (BPD-PH) – an often fatal lung disease in which the vessels carrying blood from the heart to the lungs become narrowed and dysfunctional.
Lowering blood pressure to normal levels - below currently recommended levels - did not significantly reduce the combined risk of fatal or nonfatal cardiovascular disease events in adults with type 2 diabetes who were at especially high risk for cardiovascular disease events, according to new results from the landmark Action to Control Cardiovascular Risk in Diabetes (ACCORD) clinical trial.
When seeking a cure for a disease, early detection is often the key. The same is true for eliminating invasive species. Identifying their presence in a lake before they are abundant is vital. A recent University of Illinois study successfully used environmental DNA to detect invasive clams in California and Nevada lakes. Researchers believe this tool can help identify pests before they become a problem.
› Verified 4 days ago
| Entity Name | Baptist Memorial Medical Group, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1306089206 PECOS PAC ID: 5193610228 Enrollment ID: O20101011000028 |
News Archive
Oncolytics Biotech Inc. today announced that it has received a letter of approval from the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to conduct its Phase 3 trial examining REOLYSIN in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers. This is the same trial that the Company previously reached an agreement on with the U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) process.
Findings published in the Journal of Pediatrics describe growth factors in cord blood that may identify premature infants at risk for bronchopulmonary dysplasia-associated pulmonary hypertension (BPD-PH) – an often fatal lung disease in which the vessels carrying blood from the heart to the lungs become narrowed and dysfunctional.
Lowering blood pressure to normal levels - below currently recommended levels - did not significantly reduce the combined risk of fatal or nonfatal cardiovascular disease events in adults with type 2 diabetes who were at especially high risk for cardiovascular disease events, according to new results from the landmark Action to Control Cardiovascular Risk in Diabetes (ACCORD) clinical trial.
When seeking a cure for a disease, early detection is often the key. The same is true for eliminating invasive species. Identifying their presence in a lake before they are abundant is vital. A recent University of Illinois study successfully used environmental DNA to detect invasive clams in California and Nevada lakes. Researchers believe this tool can help identify pests before they become a problem.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Hernan Alberto Sanchez Trejo, MD 965 Ridge Lake Blvd Ste 103, Memphis, TN 38120-9446 Ph: () - | Hernan Alberto Sanchez Trejo, MD 255 Baptist Blvd Ste 407, Columbus, MS 39705-2004 Ph: (662) 241-4223 |
News Archive
Oncolytics Biotech Inc. today announced that it has received a letter of approval from the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to conduct its Phase 3 trial examining REOLYSIN in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers. This is the same trial that the Company previously reached an agreement on with the U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) process.
Findings published in the Journal of Pediatrics describe growth factors in cord blood that may identify premature infants at risk for bronchopulmonary dysplasia-associated pulmonary hypertension (BPD-PH) – an often fatal lung disease in which the vessels carrying blood from the heart to the lungs become narrowed and dysfunctional.
Lowering blood pressure to normal levels - below currently recommended levels - did not significantly reduce the combined risk of fatal or nonfatal cardiovascular disease events in adults with type 2 diabetes who were at especially high risk for cardiovascular disease events, according to new results from the landmark Action to Control Cardiovascular Risk in Diabetes (ACCORD) clinical trial.
When seeking a cure for a disease, early detection is often the key. The same is true for eliminating invasive species. Identifying their presence in a lake before they are abundant is vital. A recent University of Illinois study successfully used environmental DNA to detect invasive clams in California and Nevada lakes. Researchers believe this tool can help identify pests before they become a problem.
› Verified 4 days ago
Kenneth Brian Boyd, D.O. Surgery Medicare: Accepting Medicare Assignments Practice Location: 255 Baptist Blvd Ste 407, Columbus, MS 39705 Phone: 662-241-4223 Fax: 662-241-4460 | |
Jerry L Stennett, M.D. Surgery Medicare: Medicare Enrolled Practice Location: 255 Baptist Blvd, Ste 407, Columbus, MS 39705 Phone: 662-241-4223 Fax: 662-241-4460 | |
Gerry L Jeffcoat, M.D. Surgery Medicare: Not Enrolled in Medicare Practice Location: 255 Baptist Blvd, Ste 307, Columbus, MS 39705 Phone: 662-328-1862 Fax: 662-328-7597 | |
Dr. James Bradley Beckham, M.S., M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 255 Baptist Blvd Ste 307, Columbus, MS 39705 Phone: 662-328-1862 Fax: 662-328-7597 | |
Dr. Jan T Mcclanahan, MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 255 Baptist Blvd., Suite 407, Columbus, MS 39705 Phone: 662-241-4223 Fax: 662-241-4460 | |
Dr. Richard C. Vallette, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 255 Baptist Blvd., Ste. 407, Columbus, MS 39705 Phone: 662-241-4223 Fax: 662-241-4460 |